questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Molécules d'interaction stromale
Molécules d'interaction stromale : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Molécules d'interaction stromale : Questions médicales les plus fréquentes",
"headline": "Molécules d'interaction stromale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Molécules d'interaction stromale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Molécules d'interaction stromale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines membranaires",
"url": "https://questionsmedicales.fr/mesh/D008565",
"about": {
"@type": "MedicalCondition",
"name": "Protéines membranaires",
"code": {
"@type": "MedicalCode",
"code": "D008565",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Molécule-1 d'interaction stromale",
"alternateName": "Stromal Interaction Molecule 1",
"url": "https://questionsmedicales.fr/mesh/D000071737",
"about": {
"@type": "MedicalCondition",
"name": "Molécule-1 d'interaction stromale",
"code": {
"@type": "MedicalCode",
"code": "D000071737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.875.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Molécule-2 d'interaction stromale",
"alternateName": "Stromal Interaction Molecule 2",
"url": "https://questionsmedicales.fr/mesh/D000071738",
"about": {
"@type": "MedicalCondition",
"name": "Molécule-2 d'interaction stromale",
"code": {
"@type": "MedicalCode",
"code": "D000071738",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.875.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Molécules d'interaction stromale",
"alternateName": "Stromal Interaction Molecules",
"code": {
"@type": "MedicalCode",
"code": "D000071736",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Peter B Stathopulos",
"url": "https://questionsmedicales.fr/author/Peter%20B%20Stathopulos",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca."
}
},
{
"@type": "Person",
"name": "Paul Sohn",
"url": "https://questionsmedicales.fr/author/Paul%20Sohn",
"affiliation": {
"@type": "Organization",
"name": "Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN."
}
},
{
"@type": "Person",
"name": "Wenting Wu",
"url": "https://questionsmedicales.fr/author/Wenting%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN."
}
},
{
"@type": "Person",
"name": "Marjan Slak Rupnik",
"url": "https://questionsmedicales.fr/author/Marjan%20Slak%20Rupnik",
"affiliation": {
"@type": "Organization",
"name": "Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Chih-Chun Lee",
"url": "https://questionsmedicales.fr/author/Chih-Chun%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "ANNEXIN A1: Roles in Placenta, Cell Survival, and Nucleus.",
"datePublished": "2022-06-29",
"url": "https://questionsmedicales.fr/article/35805141",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells11132057"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study on lipid nanomicelles targeting placenta for the treatment of preeclampsia.",
"datePublished": "2022-06-19",
"url": "https://questionsmedicales.fr/article/35502921",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/1061186X.2022.2068558"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk of Severe Maternal Morbidity in Patients with Placenta Accreta Spectrum Disorders Referred from Rural Communities to a Regional Placenta Accreta Spectrum Center.",
"datePublished": "2023-07-11",
"url": "https://questionsmedicales.fr/article/37433315",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-2126-7337"
}
},
{
"@type": "ScholarlyArticle",
"name": "A genome scale transcriptional regulatory model of the human placenta.",
"datePublished": "2024-06-28",
"url": "https://questionsmedicales.fr/article/38941464",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/sciadv.adf3411"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of 2D and 3D oxygen-enhanced MRI of the placenta.",
"datePublished": "2024-05-22",
"url": "https://questionsmedicales.fr/article/38776318",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0302623"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'interaction stromale",
"item": "https://questionsmedicales.fr/mesh/D000071736"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Molécules d'interaction stromale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Molécules d'interaction stromale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Molécules d'interaction stromale",
"description": "Comment diagnostiquer une interaction stromale ?\nQuels tests sont utilisés pour les molécules stromales ?\nLes marqueurs stromaux sont-ils spécifiques ?\nPeut-on détecter les molécules stromales par imagerie ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Molécules d'interaction stromale",
"description": "Quels symptômes sont liés aux interactions stromales ?\nLes interactions stromales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les tumeurs ?\nLes symptômes sont-ils précoces ou tardifs ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Molécules d'interaction stromale",
"description": "Peut-on prévenir les interactions stromales ?\nQuels modes de vie aident à prévenir les tumeurs ?\nLes dépistages réguliers sont-ils utiles ?\nL'éducation sur le cancer est-elle importante ?\nLes vaccins peuvent-ils prévenir les tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Molécules d'interaction stromale",
"description": "Quels traitements ciblent les molécules stromales ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires des traitements ?\nComment les traitements sont-ils personnalisés ?\nLes traitements sont-ils combinés ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Molécules d'interaction stromale",
"description": "Quelles complications peuvent survenir ?\nLes interactions stromales aggravent-elles les complications ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Molécules d'interaction stromale",
"description": "Quels sont les facteurs de risque des interactions stromales ?\nL'alimentation influence-t-elle les risques ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un risque ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une interaction stromale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les molécules stromales ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale."
}
},
{
"@type": "Question",
"name": "Les marqueurs stromaux sont-ils spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les molécules stromales par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux interactions stromales ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale."
}
},
{
"@type": "Question",
"name": "Les interactions stromales causent-elles des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les tumeurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils précoces ou tardifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les interactions stromales ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels modes de vie aident à prévenir les tumeurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales."
}
},
{
"@type": "Question",
"name": "L'éducation sur le cancer est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils prévenir les tumeurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les molécules stromales ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de tumeur et la nature des interactions stromales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils combinés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression tumorale, la résistance au traitement et la métastase."
}
},
{
"@type": "Question",
"name": "Les interactions stromales aggravent-elles les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des interactions stromales ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut influencer l'inflammation et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines est-elle un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer."
}
}
]
}
]
}
The unbiased approaches of the last decade have enabled the collection of new data on the biology of annexin A1 (ANXA1) in a variety of scientific aspects, creating opportunities for new biomarkers an...
In view of the serious clinical harm of preeclampsia and the lack of effective treatment methods, a PEG-modified lipid hybrid micelle was designed with a folic acid molecule on the surface, containing...
The primary objective of this study was to assess the risk of severe maternal morbidity (SMM) experienced by patients residing in rural communities when delivered by a multidisciplinary team within a ...
This was a retrospective cohort study of patients who had PAS histopathological confirmation and delivery at our institution from 2005 to 2022. Our objective was to determine the relationship between ...
During the study period, 139 patients were managed by cesarean hysterectomy with confirmed PAS histopathology. Of these, 94 (67.6%) were from our urban community and 45 (32.4%) were from surrounding r...
Patients with PAS experience high rates of SMM. Geographic distance to a PAS center appears to significantly impact the overall morbidity a patient experiences. Further research is warranted to addres...
Gene regulation is essential to placental function and fetal development. We built a genome-scale transcriptional regulatory network (TRN) of the human placenta using digital genomic footprinting and ...
Oxygen-Enhanced Magnetic Resonance Imaging (OE-MRI) of the human placenta is potentially a sensitive marker of in vivo oxygenation. This methodological study shows that full coverage of the placenta i...
The study of pathologic diagnosis of placental TB is rare. The aim of this study is analyzing the pathomorphological characteristics of tuberculosis (TB) placenta during pregnancy and its clinical sig...
Nineteen cases of placental tissue specimens during pregnancy were collected from June 2015 to February 2022 at Shanghai Public Health Clinical Center, the only inpatient center for pregnant women wit...
Among the 19 cases, 7 cases caused intrauterine stillbirth, 3 cases received artificial abortion required by the pregnant woman, the other 9 cases received standard delivery and the infants survived, ...
Combining acid-fast staining and molecular pathological testing is helpful for accurately diagnosing placental TB....
Surgical training experience in obstetrics-gynecology (OB-GYN) residency and fellowship training, particularly in open abdominal surgeries has declined over the last 2 decades. This is due, in part, d...
Placenta previa increases the risks of obstetrical complications. Many studies have reported a link between various ABO blood types and pregnancy complications. This study is aimed at describing and c...
Data for this study was obtained from a retrospective cohort study between January 1, 2014, and June 30, 2019, of all clinically confirmed placenta previa in a university-based tertiary medical center...
1678 participants with placenta previa were included in this study. The highest participants were blood type O with 666 (39.7%), followed by type A with 508 (30.3%) and type B with 395 (23.5%), and th...
Type AB blood may be a potential risk factor for women with placenta previa. This finding may help provide any obstetrician to predict the risk of complication for placenta previa women by the ABO blo...
Due to the advancements in pediatric cardiothoracic surgery and medical management, more individuals with congenital heart disease are reaching reproductive age. It is well established that individual...
Placenta accreta spectrum (PAS) is a condition associated with massive postpartum bleeding and maternal mortality. Management guidelines published in high income countries recommend the participation ...
The aim of this consensus is to draft general recommendations for the treatment of PAS in Colombia....
Twenty-three panelists took part in the consensus with their answers to 31 questions related to the treatment of PAS. The panelists were selected based on participation in two surveys designed to dete...
The consensus draftedfive recommendations, integrating the answers of the panelists. Recommendation 1. Primary care institutions must undertake active search of PAS in patients with risk factors: plac...
It is our hope that this first Colombian consensus on PAS will serve as a basis for additional discussions and collaborations that can result in improved clinical outcomes for women affected by this c...